Diogo Martins Branco, Medical Oncologist at ESMO, shared a post on LinkedIn:
“Inspiring session about Tumour Agnostic drug development this morning at ESMO Rare Cancers 2025.
Benedikt Westphalen, our ESMO – European Society for Medical Oncology Precision Oncology Task Force Chair, pinpointing the potential role of The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) on the roadmap of drug development.
Delighted to note the momentum of innovative Precision Oncology and high-quality Real Word Data coming together as a solution for generating confirmatory body of evidence for tumour-agnostic indications.
The ESMO – European Society for Medical Oncology is paving the path to improve the care of patients with rare cancers and common cancers with rare molecular alterations.”‘
